Share
849 Posts.
lightbulb Created with Sketch. 97
clock Created with Sketch. 22/06/21
15:51
Share
Originally posted by hottod:
↑
Arrowhead Pharmaceuticals (ARWR) hasn’t been brought to my attention by a broker/advisor and I’m certainly not suggesting that PYC will be valued at US$9bn within three years. But I do view Arrowhead as an example of what can be achieved in this space within a relatively short timeframe, by leveraging the right delivery platform.Our liver directed pipeline already has six candidates in clinical studies, with additional undisclosed programs in preclinical development. In addition, as you’ve seen over the last couple years, once we achieve clinical validation, each successive candidate in the same cell type builds on learnings from each program that went before it. We believe this provides a higher probability of success and lower risk profile than other modalities. We expect our pipeline to potentially double in size over the next few years.
Expand
apologies. I didn’t mean to imply you thought that - I was just surprised at the coincidence of the mentioning of arrowhead - something that surprised me even more when googling arrowhead was seeing them presenting tonight at this LifeSci Partners Genetic Medicine Summit conference and then seeing who else was presenting!https://web.cvent.com/event/c5379a45-c222-4ee4-97d2-551d19fea636/summary
(20min delay)